PT2908805T - Formulações de levodopa para alívio rápido da doença de parkinson - Google Patents

Formulações de levodopa para alívio rápido da doença de parkinson

Info

Publication number
PT2908805T
PT2908805T PT138493887T PT13849388T PT2908805T PT 2908805 T PT2908805 T PT 2908805T PT 138493887 T PT138493887 T PT 138493887T PT 13849388 T PT13849388 T PT 13849388T PT 2908805 T PT2908805 T PT 2908805T
Authority
PT
Portugal
Prior art keywords
parkinson
disease
rapid relief
levodopa formulations
levodopa
Prior art date
Application number
PT138493887T
Other languages
English (en)
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of PT2908805T publication Critical patent/PT2908805T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT138493887T 2012-10-22 2013-10-21 Formulações de levodopa para alívio rápido da doença de parkinson PT2908805T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716740P 2012-10-22 2012-10-22
US201361813605P 2013-04-18 2013-04-18
US201361813725P 2013-04-19 2013-04-19

Publications (1)

Publication Number Publication Date
PT2908805T true PT2908805T (pt) 2021-09-10

Family

ID=50545142

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138493887T PT2908805T (pt) 2012-10-22 2013-10-21 Formulações de levodopa para alívio rápido da doença de parkinson

Country Status (18)

Country Link
US (1) US20150328175A1 (pt)
EP (2) EP2908805B1 (pt)
JP (2) JP2016500690A (pt)
KR (2) KR20150102960A (pt)
CN (2) CN110812350A (pt)
AU (3) AU2013334949B2 (pt)
BR (1) BR112015009088A2 (pt)
CA (1) CA2888994C (pt)
DK (1) DK2908805T3 (pt)
ES (1) ES2886529T3 (pt)
HK (2) HK1212258A1 (pt)
MX (2) MX2015005038A (pt)
NZ (1) NZ708414A (pt)
PL (1) PL2908805T3 (pt)
PT (1) PT2908805T (pt)
RU (2) RU2685718C2 (pt)
SG (2) SG10201804985QA (pt)
WO (1) WO2014066208A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ708415A (en) * 2012-10-22 2018-11-30 Civitas Therapeutics Inc Reducing inter-patient variability of levodopa plasma concentrations
BR112015010601B1 (pt) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US20170296498A1 (en) * 2014-04-21 2017-10-19 Civitas Therapeutics, Inc. Rapid Relief of Motor Fluctuations in Parkinson's Disease
KR20200118033A (ko) * 2018-01-05 2020-10-14 임펠 뉴로파마 인코포레이티드 정밀 후각기관 장치에 의한 레보도파 분말의 비강내 전달
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
EP1531798B1 (en) * 2002-03-20 2012-06-06 Civitas Therapeutics, Inc. Pulmonary delivery for levodopa
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders

Also Published As

Publication number Publication date
AU2013334949A1 (en) 2015-06-11
AU2013334949B2 (en) 2018-08-09
EP2908805A1 (en) 2015-08-26
RU2015119377A (ru) 2016-12-10
AU2018253538A1 (en) 2018-11-22
PL2908805T3 (pl) 2021-12-27
NZ708414A (en) 2018-11-30
HK1212623A1 (zh) 2016-06-17
WO2014066208A1 (en) 2014-05-01
RU2019111096A (ru) 2020-10-12
KR20210075224A (ko) 2021-06-22
AU2020250325A1 (en) 2020-11-12
CN110812350A (zh) 2020-02-21
EP2908805A4 (en) 2016-07-06
EP2908805B1 (en) 2021-06-09
MX2021014782A (es) 2023-03-23
ES2886529T3 (es) 2021-12-20
MX2015005038A (es) 2015-12-01
SG11201503129RA (en) 2015-05-28
CN104884046A (zh) 2015-09-02
KR20150102960A (ko) 2015-09-09
DK2908805T3 (da) 2021-09-13
US20150328175A1 (en) 2015-11-19
JP2018150339A (ja) 2018-09-27
HK1212258A1 (en) 2016-06-10
EP3943080A1 (en) 2022-01-26
BR112015009088A2 (pt) 2017-07-04
CA2888994A1 (en) 2014-05-01
JP2016500690A (ja) 2016-01-14
CA2888994C (en) 2022-10-04
RU2685718C2 (ru) 2019-04-23
SG10201804985QA (en) 2018-07-30
AU2018253538B2 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
IL266648B (en) A method for treating Parkinson's disease
IL269511A (en) New therapeutic approaches to treat Parkinson's disease
HK1210968A1 (en) Compositions and treatment for eye diseases and disorders
ES2627541T8 (es) Métodos para tratar la enfermedad de Parkinson
HK1212623A1 (zh) 用於快速緩解帕金森病的左旋多巴製劑
IL233572A0 (en) A pharmaceutical preparation containing a mixture with fixed doses for the treatment of Parkinson's disease
GB201206382D0 (en) Parkinson's disease biomarker
EP2678009A4 (en) CYSTAMINE ANALOGS FOR THE TREATMENT OF PARKINSON'S DISEASE
EP2906225A4 (en) METHODS OF TREATING KENNEDY'S DISEASE
EP2841077A4 (en) NUTRITIONAL FIBER COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISORDERS
HK1199410A1 (en) Composition for enhancing defenses of skin
EP2854539A4 (en) PHOSPHONATE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PL2730279T3 (pl) Preparaty cynakalcetu o natychmiastowym uwalnianiu
TWI560195B (en) Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
IL241482B (en) A method for treating Parkinson's disease
GB201205857D0 (en) Skin care formulations